Skip Navigation


Annals of Oncology Advance Access originally published online on November 12, 2007
Annals of Oncology 2007 18(12):1927-1934; doi:10.1093/annonc/mdm201
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
18/12/1927    most recent
mdm201v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (11)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kaufmann, M.
Right arrow Articles by Loibl, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kaufmann, M.
Right arrow Articles by Loibl, S.
Related Collections
Right arrow 2007 - Review Articles
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 European Society for Medical Oncology

reviews

Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006

M. Kaufmann1,*, G. von Minckwitz1,2, H. D. Bear3, A. Buzdar4, P. McGale5, H. Bonnefoi6, M. Colleoni7, C. Denkert8, W. Eiermann9, R. Jackesz10, A. Makris11, W. Miller12, J.-Y. Pierga13, V. Semiglazov14, A. Schneeweiss15, R. Souchon16, V. Stearns17, M. Untch18 and S. Loibl1,2

1 J. W. Goethe-University, Frankfurt am Main
2 German Breast Group, Neu-Isenburg/Frankfurt am Main, Germany
3 Division of Surgical Oncology the Massey Cancer Center at Virginia Commonwealth University, Richmond, Virginia, USA and National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, Pennsylvania
4 The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA
5 Early Breast Cancer Trialists' Collaborative Group, Oxford
6 EORTC Breast Cancer Group, Hôpitaux Universitaires des Genéve, Geneva, Switzerland
7 Istituto Europeo di Oncologia Milan, Italy
8 Charité, Institute of Pathology, Campus Mitte, Berlin
9 Krankenhaus vom Roten Kreuz, Frauenklinik, München, Germany
10 Universtitätsklinik für Chirurgie, Wien, Austria
11 Mount Vernon Hospital, Northwood, Middlesex
12 University of Edinburgh, Western General Hospital, Edinburgh, UK
13 Institut Curie, Department of Medical Oncology, Paris, France
14 NN Petrov Research Inst of Oncology, St. Petersburg, Russia
15 Ruprecht-Karls-Universität Heidelberg, Heidelberg
16 Allgemeines Krankenhaus Hagen, Hagen, Germany
17 The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
18 Helios Klinikum Berlin-Buch, Berlin Germany

Correspondence to: Prof. M. Kaufmann, Department of Obstetrics and Gynecology, J.W.Goethe-University Hospital, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany. Tel: +49-69-6301-5115; Fax: +49-69-6301-4717; E-mail: M.Kaufmann{at}em.uni-frankfurt.de

Neoadjuvant (primary systemic) treatment has become a standard option for primary operable disease for patients who are candidates for adjuvant systemic chemotherapy, irrespective of the size of the tumor. Because of new treatments and new understandings of breast cancer, however, recommendations published in 2006 regarding neoadjuvant treatment for operable disease required updating. Therefore, a third international panel of representatives of a number of breast cancer clinical research groups was convened in September 2006 to update these recommendations. As part of this effort, data published to date were critically reviewed and indications for neoadjuvant treatment were newly defined.

Key words: breast cancer, neoadjuvant therapy, recommendations

Received for publication April 5, 2007. Accepted for publication April 13, 2007.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Anticancer ResHome page
L. MIGLIETTA, P. VANELLA, L. CANOBBIO, M. A. PARODI, P. GUGLIELMINI, and F. BOCCARDO
Clinical and Pathological Response to Primary Chemotherapy in Patients with Locally Advanced Breast Cancer Grouped According to Hormonal Receptors, Her2 Status, Grading and Ki-67 Proliferation Index
Anticancer Res, May 1, 2009; 29(5): 1621 - 1625.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
G. Mustacchi, M. Mansutti, C. Sacco, S. Barni, A. Farris, M. Cazzaniga, M. Cozzi, and C. Dellach
Neo-adjuvant exemestane in elderly patients with breast cancer: a phase II, multicentre, open-label, Italian study
Ann. Onc., April 1, 2009; 20(4): 655 - 659.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J.-Y. Pierga, F.-C. Bidard, C. Mathiot, E. Brain, S. Delaloge, S. Giachetti, P. de Cremoux, R. Salmon, A. Vincent-Salomon, and M. Marty
Circulating Tumor Cell Detection Predicts Early Metastatic Relapse After Neoadjuvant Chemotherapy in Large Operable and Locally Advanced Breast Cancer in a Phase II Randomized Trial
Clin. Cancer Res., November 1, 2008; 14(21): 7004 - 7010.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.